Amylozie

Amylozie is not a standard term in medical literature. It may be a misspelling or regional variant of amyloidosis, a group of diseases defined by extracellular deposition of insoluble protein fibrils called amyloid in tissues and organs.

Amyloidosis occurs when misfolded precursor proteins accumulate as amyloid fibrils, disrupting tissue structure and function. The condition can affect virtually any organ, most often the heart, kidneys, liver, nerves, and gastrointestinal tract.

The major forms are AL amyloidosis, caused by misfolded light chains produced by abnormal plasma cells; AA amyloidosis, linked to chronic inflammatory conditions and elevated serum amyloid A protein; and transthyretin-related amyloidosis (ATTR), due to deposits of transthyretin either inherited or age-related. Other less common forms arise from mutations in additional precursor proteins.

Diagnosis relies on tissue biopsy of affected areas or accessible margins, stained with Congo red to show apple-green birefringence under polarized light. Additional tests include blood and urine protein electrophoresis, free light-chain assays, and organ-specific imaging to assess function and involvement.

Treatment targets the underlying precursor protein and provides organ-supportive care. AL amyloidosis treatment often involves chemotherapy approaches and, in suitable patients, stem cell transplantation; ATTR forms may be managed with therapies that stabilize or silence transthyretin production, alongside comprehensive supportive measures. The choice of therapy depends on the amyloid type and the extent of organ involvement.

Prognosis varies by type and organ involvement; early diagnosis and management improve outcomes and quality of life. While amylozie as a term is uncommon, understanding amyloidosis helps explain a spectrum of related disorders characterized by abnormal protein deposition.